Literature DB >> 14508884

MBI-226. Micrologix/Fujisawa.

Richard E Isaacson1.   

Abstract

Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14508884

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  10 in total

1.  Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity.

Authors:  Helio S Sader; Kelley A Fedler; Robert P Rennie; Shelley Stevens; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.

Authors:  Thomas R Fritsche; Paul R Rhomberg; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

Review 3.  On the physiology and pathophysiology of antimicrobial peptides.

Authors:  Roland Pálffy; Roman Gardlík; Michal Behuliak; Ludevit Kadasi; Jan Turna; Peter Celec
Journal:  Mol Med       Date:  2008-11-10       Impact factor: 6.354

Review 4.  Multifunctional antimicrobial peptides: therapeutic targets in several human diseases.

Authors:  Mohamed Zaiou
Journal:  J Mol Med (Berl)       Date:  2007-01-10       Impact factor: 4.599

Review 5.  Sequential and Structural Aspects of Antifungal Peptides from Animals, Bacteria and Fungi Based on Bioinformatics Tools.

Authors:  Karuna Singh; Jyoti Rani
Journal:  Probiotics Antimicrob Proteins       Date:  2016-06       Impact factor: 4.609

6.  Treatment and prevention of Staphylococcus epidermidis experimental biomaterial-associated infection by bactericidal peptide 2.

Authors:  Paulus H S Kwakman; Anje A te Velde; Christina M J E Vandenbroucke-Grauls; Sander J H van Deventer; Sebastian A J Zaat
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

Review 7.  The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation.

Authors:  Seong-Cheol Park; Yoonkyung Park; Kyung-Soo Hahm
Journal:  Int J Mol Sci       Date:  2011-09-16       Impact factor: 5.923

8.  Cathelicidins from the bullfrog Rana catesbeiana provides novel template for peptide antibiotic design.

Authors:  Guiying Ling; Jiuxiang Gao; Shumin Zhang; Zeping Xie; Lin Wei; Haining Yu; Yipeng Wang
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

9.  Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.

Authors:  Bonita Durnaś; Urszula Wnorowska; Katarzyna Pogoda; Piotr Deptuła; Marzena Wątek; Ewelina Piktel; Stanisław Głuszek; Xiaobo Gu; Paul B Savage; Katarzyna Niemirowicz; Robert Bucki
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

Review 10.  Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.

Authors:  María Escobar-Salom; Gabriel Torrens; Elena Jordana-Lluch; Antonio Oliver; Carlos Juan
Journal:  Biol Rev Camb Philos Soc       Date:  2022-01-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.